Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel aims to stop chemo side effect that makes hands hurt

NCT ID NCT07457671

Prevention Sponsor: Tarian Pharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a gel called TAR-0520 to see if it can prevent hand-foot syndrome, a painful skin reaction caused by the chemotherapy drug capecitabine. About 25 people with breast or colorectal cancer will apply the gel to their hands twice daily for 12 weeks. Their feet will not be treated and will serve as a comparison. The goal is to check if the gel is safe and reduces the severity of hand-foot syndrome.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TAR-0520 gel
What this could lead to
If it works, this could point toward a way to prevent painful hand-foot syndrome in cancer patients taking capecitabine, improving their quality of life.
What could go wrong
This is a small, early-phase study with only 25 people. It may not show clear benefit, and the gel could cause local skin reactions or not reduce symptoms enough to matter.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Medical diagnosis of breast or colorectal cancer planned to be treated with capecitabine * at a dose \> 1000mg/m² twice daily every 2 out of 3 weeks as single agent chemotherapy * Patients with life expectancy graeter than 12 weeks Exclusion Criteria: * Patient with medical history of capecitabine treatment * patient with pre-existing neuropathy confounding assessement of HFS * Patient with Raynaud's syndrome or other vascular peripheral disorders * Patient with dermatological lesions on hands or foot

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer colorectal cancer hand-foot syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hand and foot syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instiut Paoli-Calmettes

    Marseille, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.